X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dabur subsidiary plans line extensions for Spirulina, new products - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Dec 23, 1999

    Dabur subsidiary plans line extensions for Spirulina, new products

    Dabur subsidiary Sanat Products (Sanat), manufacturers of ayurveda and herbal products under the Sunova brand name is planning a line extension for its largest-selling Spirulina range.

    Spirulina is one of the richest health foods in the world referred to as the ‘greatest super food’ by several international bodies. It is derived from algae at the company’s facility in Tamilnadu. It is also used by NASA scientists during space missions.

    The line extension could be into syrups, cookies and candies. It is also planning a Vitamin C tablet around the Spirulina product.

    Sanat also plans to launch three to four new products every year. Apart from the recently launched gel for arthritis (Nopane gel), it also produces Rejuva, a stress and vitality capsule and Bioslim, a slimming capsule. It is also looking at launching products to cure diabetes, hair fall and HIV Infections.

    Spirulina being an established product implies that the company need not prove the efficacy of the product all over again. It would however imply a much higher ad spend in order to increase market penetration.

    Further for the new products, the areas/diseases which Dabur is targeting not have a very wide market in India but also enjoy an extremely huge export market. As it is, Sanat’s domestic sales to export ratio stands at 50:50 and it will continue to remain that way.

    Market View:
    Dabur has been re-rated post implementation of a new business model. The model focused on family, health care and other ayurvedic products and exiting the non-core business, aggressive brand building through higher ad spend, recruitment of professionals as CEO and divisional heads and improvement in distribution and supply chain management. Although the market does not expect any further re–rating in the near term, the stock should continue to out perform on the back of its superior earnings growth.

     

     

    Equitymaster requests your view! Post a comment on "Dabur subsidiary plans line extensions for Spirulina, new products". Click here!

      
     

    More Views on News

    Marico: Earnings Hit by Lower Volumes and Firming Input Prices (Quarterly Results Update - Detailed)

    Aug 9, 2017

    While GST implementation brought down volumes and profitability in the short run, Marico remains optimistic in the long run.

    Dabur: Premiumisation Efforts to Keep Competition at Bay? (Quarterly Results Update - Detailed)

    May 4, 2016

    Dabur announced its results for the quarter ended March 2016. The company reported a revenue growth of 11% YoY during the quarter, while profits moved up by 17% YoY.

    Dabur: Moving along... (Quarterly Results Update - Detailed)

    Nov 2, 2015

    Dabur announced its results for the quarter ended September 2015. The company reported a revenue growth of 9% YoY during the quarter, while profits moved up by 19% YoY.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    DABUR SHARE PRICE


    Aug 21, 2017 (Close)

    TRACK DABUR

    DABUR 8-QTR ANALYSIS

    Detailed Quarterly Results With Charts

    COMPARE DABUR WITH

    MARKET STATS